Results 11 to 20 of about 12,335 (206)

Pediatric medulloblastoma express immune checkpoint B7-H3 [PDF]

Clinical and Translational Oncology, 2022
PURPOSE: Medulloblastomas (MB) are highly malignant brain tumors that predominantly occur in young infants. Immunotherapy to boost the immune system is emerging as a novel promising approach, but is often hampered by inhibitory immune checkpoints. In the
Bovenschen, N, Broekhuizen, R, Li, S, Monnikhof, M, Poolen, G C, Schipper, J G, Van Hecke, W, van Vliet, L C, Vermeulen, J F   +8 more
core   +5 more sources

B7-H3 and Its Role in Antitumor Immunity [PDF]

Journal of Immunology Research, 2010
B7-H3 is one of the most recently identified members of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T-cell response.
Friess, Helmut, Hedderich, Dennis M., Kleeff, Jörg, Loos, Martin   +3 more
core   +6 more sources

ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors

Cancer Cell International, 2023
Background The B7-H3 protein, encoded by the CD276 gene, is a member of the B7 family of proteins and a transmembrane glycoprotein. It is highly expressed in various solid tumors, such as lung and breast cancer, and has been associated with limited ...
Seol Hwa Shin, Eun Jin Ju, Jin Park, Eun Jung Ko, Mi Ri Kwon, Hye Won Lee, Ga Won Son, Yun-Yong Park, Yeon Joo Kim, Si Yeol Song, Sangkwang Lee, Beom Seok Seo, Jin-A Song, Sangbin Lim, Doohwan Jung, Sunyoung Kim, Hyangsook Lee, Seok Soon Park, Seong-Yun Jeong, Eun Kyung Choi   +19 more
doaj   +3 more sources

B7-H3 Expression in Breast Cancer and Brain Metastasis [PDF]

International Journal of Molecular Sciences
Brain metastasis is a significant challenge for some breast cancer patients, marked by its aggressive nature, limited treatment options, and poor clinical outcomes. Immunotherapies have emerged as a promising avenue for brain metastasis treatment. B7-H3 (
Beecher, Kate, Duijf, Pascal HG, Feng, Yufan, Jat, Parmjit S, Joshi, Vaibhavi, Lakhani, Sunil R, Lim, Malcolm, McCart Reed, Amy E, Simpson, Peter T, Stacey, Andrew   +9 more
core   +4 more sources

Expression characteristic of 4Ig B7-H3 and 2Ig B7-H3 in acute myeloid leukemia [PDF]

Bioengineered, 2021
4IgB7-H3 (4Ig) and 2IgB7-H3 (2Ig) expression characteristics in acute myeloid leukemia (AML) remain unknown. This study investigated mRNA and membrane protein expression of two B7-H3 isoforms in AML cell lines and de novo patients by using RT-PCR and flow cytometry, and analyzed the B7-H3 promoter methylation state by utilizing RQ-MSP.
Zhang, Wei, Zhang, Lingyi, Qian, Jun, Lin, Jiang, Chen, Qiaoyun, Yuan, Qian, Zhou, Jingdong, Zhang, Tingjuan, Shi, Jinning, Zhou, Hong   +9 more
openaire   +2 more sources

B7-H3/CD276: An Emerging Cancer Immunotherapy [PDF]

Frontiers in Immunology, 2021
Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target
Wu-Tong Zhou, Wei-Lin Jin, Wei-Lin Jin
openaire   +3 more sources

B7-H3 and digestive system cancers [PDF]

European Journal of Inflammation, 2021
Digestive system cancers (DSC) are the most common cancers worldwide and often associated with poor prognosis because of their characteristics of invasive and metastatic. Thus, it is particularly necessary to find novel molecular targets for early diagnosis, as well as targeted treatment of DSC.
Liyun Zhou, Zhenhua Jiang, Jing Gu, Wenhui Gu, Shuangyin Han   +4 more
openaire   +2 more sources

Cloning and characterization of porcine 4Ig-B7-H3: a potent inhibitor of porcine T-cell activation. [PDF]

PLoS ONE, 2011
BACKGROUND: Members of the B7 superfamily costimulate the proliferation of lymphocytes during the initiation and maintenance of antigen-specific humoral and cell-mediated immune responses. B7-H3 (CD276) is a newly identified member of the B7 superfamily.
Weiwei Chen, Zhibo Hou, Chunman Li, Sheng Xiong, Henggui Liu   +4 more
doaj   +1 more source

B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia

European Journal of Medical Research, 2023
Background and aims Chimeric antigen receptor (CAR)-T cell therapy is a novel type of immunotherapy. However, the use of CAR-T cells to treat acute myeloid leukaemia (AML) has limitations.
Shuangshuang Fan, Tian Wang, Fengtao You, Tingting Zhang, Yafen Li, Cheng Ji, Zhichao Han, Binjie Sheng, Xiaochen Zhai, Gangli An, Huimin Meng, Lin Yang   +11 more
doaj   +1 more source

B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression [PDF]

, 2021
New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In this study, we explored the immunosuppressive effect of B7-H3 (CD276) via the CCL2–
Abiko, Kaoru, Baba, Tsukasa, Hamanishi, Junzo, Horikawa, Naoki, Hosoe, Yuko, Mandai, Masaki, Matsumura, Noriomi, Mise, Nathan, Mise, Yuka, Miyamoto, Taito, Murakami, Ryusuke, Takamatsu, Shiro, Taki, Mana, Tanigaki, Kenji, Ukita, Masayo, Yamaguchi, Ken, Yamanoi, Koji   +16 more
core   +1 more source